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HER2 challenge contest: a detailed assessment of automated HER2 scoring algorithms in
whole slide images of breast cancer tissues
Aims: Evaluating expression of the human epidermal
growth factor receptor 2 (HER2) by visual examina-
tion of immunohistochemistry (IHC) on invasive
breast cancer (BCa) is a key part of the diagnostic
assessment of BCa due to its recognized importance
as a predictive and prognostic marker in clinical prac-
tice. However, visual scoring of HER2 is subjective,
and consequently prone to interobserver variability.
Given the prognostic and therapeutic implications of
HER2 scoring, a more objective method is required.
In this paper, we report on a recent automated HER2
scoring contest, held in conjunction with the annual
PathSoc meeting held in Nottingham in June 2016,
aimed at systematically comparing and advancing
the state-of-the-art artificial intelligence (AI)-based
automated methods for HER2 scoring.
Methods and results: The contest data set comprised
digitized whole slide images (WSI) of sections from 86
cases of invasive breast carcinoma stained with both
haematoxylin and eosin (H&E) and IHC for HER2.
The contesting algorithms predicted scores of the IHC
slides automatically for an unseen subset of the data
set and the predicted scores were compared with the
‘ground truth’ (a consensus score from at least two
experts). We also report on a simple ‘Man versus
Machine’ contest for the scoring of HER2 and show
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that the automated methods could beat the pathology
experts on this contest data set.
Conclusions: This paper presents a benchmark for
comparing the performance of automated algorithms
for scoring of HER2. It also demonstrates the enor-
mous potential of automated algorithms in assisting
the pathologist with objective IHC scoring.
Keywords: automated HER2 scoring, biomarker quantification, breast cancer, digital pathology, quantitative
immunohistochemistry
Introduction
The adoption of image analysis in digital pathology
has received significant attention recently due to the
availability of digital slide scanners and the increas-
ing importance of tissue-based biomarkers in strati-
fied medicine.1 Advances in software development
and an upwards trend in computational capacity
have also caused an upsurge of interest in digital
pathology.
Breast cancer (BCa) is the most commonly diag-
nosed cancer among women, and the second leading
cause of death worldwide.2 According to Cancer
Research UK, the risk for women being diagnosed
with breast cancer is one in eight in the United King-
dom, and approximately 11 600 women died from
breast cancer in 2012.3 In routine diagnostic practice
of BCa, tumour tissue is stained with haematoxylin
and eosin (H&E) and then examined under the optical
microscope for morphological assessment, including
grade. In addition, tissues are stained by immunohis-
tochemistry (IHC) to evaluate biomarker expression
for prognostic and predictive purposes. This conven-
tional method of diagnosis by visual examination is
considered accurate in most areas, but is known to
suffer from inter- and intra-observer variability in
some areas, such as diagnosis of atypical hyperplasia
and reporting of histological grade.4–6 Digital
pathology offers significant potential for improvement
to overcome the subjectivity and improve
reproducibility.
The human epidermal growth factor receptor 2
(HER2) gene is amplified in approximately 15–20% of
breast cancers.7 Gene amplification can also be identi-
fied through fluorescence in-situ hybridization (FISH).
Alternatively, as HER2 amplification results in
increased protein expression, IHC may be used. Given
the technical ease of performing IHC it has become
the preferred test, and FISH is usually performed only
when the IHC is equivocal. In practice, an expert
histopathologist will report a score between 0 and 3+
and cases scoring 0 or 1+ are classified as negative,
while cases with a score of 3+ are classed as positive.
Cases with score 2+ are classified as equivocal and
are assessed further by FISH to test for gene amplifi-
cation. Examples of the four different HER2 scores (0
to 3+) are shown in Figure 1. A summary of recom-
mended guidelines for HER2 IHC scoring criteria7 is
shown in Table 1.
Historically, up to 20% of the HER2 IHC results may
contain inaccuracies8 due to variations in the technical
quality and the subjective nature of scoring. Although
adoption of HER2 guidelines and recommendations7
have served to improve standards in HER2 testing,
challenging cases remain, especially with HER2 scores
deemed borderline between categories.
Automated IHC scoring of HER2 carries promise to
overcome the existing problems in conventional
methods. Automated scoring methods are not prone
to subjective bias, and can provide precise quantita-
tive analysis which can assist the expert pathologist
to reach a reproducible score.
The HER2 scoring contest, documented in this
paper, was organized by the University of Warwick,
the University of Nottingham and the Academic–
Industrial Collaboration for Digital Pathology (AID-
PATH) consortium (www.aidpath.eu). It was held in
conjunction with the Pathological Society of Great
Britain and Ireland meeting in Nottingham (June
2016) to provide a platform for researchers to assess
the performance of computer algorithms for auto-
mated HER2 scoring on IHC-stained slides. This paper
provides an overview of the automated methods for
HER2 scoring as presented at the contest and a ‘Man
versus Machine’ comparison of the degree of agree-
ment among histopathologists and the automated
methods for HER2 scoring. This may be considered as
an initial step towards the development of a reliable
computer-assisted diagnosis tool for HER2 scoring of
digitized BCa histology slides.
Materials and methods
E T H I C S
Ethical approval was by Nottingham Research Ethics
Committee 2 (Approval no.: REC 2020313); R&D ref-
erence (N) 03HI01.
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I M A G E D A T A A C Q U I S I T I O N A N D G R O U N D T R U T H
The histology slides for this contest were scanned on
a Hamamatsu NanoZoomer C9600, enabling the
image to be viewed from a 94 to a 940 magnifica-
tion, making the process comparable to a clinician’s
standard microscope. Generally, WSIs are gigapixel
images stored in a multiresolution pyramid structure,
where the highest resolution is 940. The contest data
set entailed 172 whole slide images (WSI) extracted
from 86 cases of invasive breast carcinomas and
included both the H&E- and HER2-stained slides. The
actual HER2 scoring is normally performed on the
IHC-stained slides, while the H&E slides assist the
expert pathologist to identify the areas of invasive
tumour and discriminate these from areas of in-situ
disease. Figure 2 shows an example of the two types
of WSIs (with a corresponding zoomed-in region of
interest) from the contest data set.
The ground truth (GT) was taken from the clinical
reports issued on the cases at a tertiary referral centre
for breast pathology (Nottingham University Hospi-
tals, NHS Trust). At this centre, each case had been
reported or reviewed by at least two specialist consul-
tant histopathologists as part of their routine practice
[preliminary reporting and multidisciplinary team
(MDT) review]. The centre provides regular internal
quality control for HER2 assessment for immunohis-
tochemistry runs and contributes and participates
regularly in the UK NEQAS (National External Qual-
ity Assessment Scheme) for immunocytochemistry
and in-situ hybridization (ICC and ISH).
C O N T E S T A N T S
A total of 105 teams from more than 28 countries
registered to access the training data set before the
end of the registration deadline. By the end of the
submission deadline (off-site contest), a total of 18
submissions from 14 teams were received for evalua-
tion. The organizers provided an opportunity to each
of the 14 teams for presenting their approach in the
contest workshop and six teams chose to present. For
the Man versus Machine contest, we received the
markings from four pathologists. The contest website
was re-opened for new submissions after concluding
the workshop. Further details regarding various
stages of the contest are described in Data S1 and
Table S1.
E V A L U A T I O N
The performance of each submitted algorithm was
evaluated based on three criteria: (1) agreement
points, (2) weighted confidence and (3) combined
Figure 1. Left to right: examples of regions of interest (800 lm in height and the same in width) from whole slide images (WSIs) scored 0,
1+ (negative), 2+ (equivocal) and 3+ (positive).
Table 1. Recommended automated human epidermal
growth factor receptor 2 (HER2) scoring criteria for
immunohistochemistry (IHC)-stained breast cancer tissue
slides7
Score Cell membrane staining pattern
Staining
assessment
0 No membrane staining or incomplete
membrane staining in <10% of invasive
tumour cells (0+) or faint/barely
perceptible or weak incomplete
membrane stainaing in 10% of tumour
cells (1+)
Negative
1+ Negative
2+ A weak to moderate complete membrane
staining is observed in >10% of tumour
cells or strong complete membrane
staining in ≤10% of tumour cells
Borderline
(equivocal)
3+ A strong (intense and uniform) complete
membrane staining is observed in >10%
of invasive tumour cells
Positive
© 2017 John Wiley & Sons Ltd, Histopathology, 72, 227–238.
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points. Each assessment criterion has a separate lea-
der-board.
The evaluation criteria were rationalized according
to the clinical significance and implications of HER2
IHC scoring as follows: in everyday clinical practice,
for a score of 0 and 1+ no herceptin is offered to the
patient; for a 3+ score, herceptin is offered. For an
IHC 2+ score, a FISH test is performed; if positive
(i.e.) there is evidence of gene amplification and her-
ceptin is offered, while for a negative result it is not
offered. The evaluation considers the impact of erro-
neous classification. For example, a score of 0/1+
being interpreted as 3+ or vice versa is a serious error
while a 2+ scored as 0/1+ denies a few patients of
valid treatment; a score of 3+ for a 2+ case bypasses
the FISH test and may treat a few cases erroneously
(which would have been FISH-negative) with toxic
drugs while a score of actual 3+ downgraded to a 2+
calls for additional expense of FISH testing, but the
end result will probably be the same and hence this
should not be regarded as a serious error. These have
been summarized in Table 2.
For agreement points, a penalty method was
employed whereby each erroneous prediction is
penalized with respect to its deviation from the GT, as
shown in Table 2A. It can be envisaged that the
agreement points may end in a tie, where the accu-
mulative points of two or more teams may be the
same. To resolve the tie, a bonus criterion was
devised as shown in Table 2B, where the decision
was made on the percentage of cells with complete
cell membrane staining (PCMS) regardless of the
(A)
(B)
Figure 2. An example whole slide image (WSI) along with a
zoomed-in cross-sectional area showing the tumour region (A)
haematoxylin and eosin (H&E)-stained slide; (B) immunohistochem-
istry (IHC)-stained slide.
Table 2. (A) Agreement points for predicted calls of
ground truth (GT), (B) bonus point criteria, when percent-
age of cells with complete cell membrane staining (PCMS)
lies in certain range of the GT value of the PCMS
Points for predicted score
(A)
Ground truth Score 0 1+ 2+ 3+
0 15 15 10 0
1+ 15 15 10 0
2+ 2.5 2.5 15 5
3+ 0 0 10 15
Ground truth score
Percentage of cells with complete cell
membrane staining (PCMS)
(B)
0 0 0
1+ 1 (PCMS < 3%) 3 (PCMS  2)
2+ 5 (PCMS  5) 2.5 (PCMS  10)
3+ 5 (PCMS  5) 2.5 (PCMS  10)
© 2017 John Wiley & Sons Ltd, Histopathology, 72, 227–238.
230 T Qaiser et al.
intensity. The bonus points were <3% introduced for
scores 2+ and 3+ as they attain more clinical signifi-
cance. For the IHC score 1+, 1 bonus point was
awarded if there was an accurate prediction of the
IHC score and PCMS <3%, while 3 bonus points were
awarded if there was an accurate prediction of the
IHC score and PCMS >3% but the predicted PCMS
value deviated only 2% from the GT. For the IHC
scores 2+ and 3+, 5 bonus points were awarded if
there was an accurate prediction of the IHC score
and PCMS deviated only 5% from the GT. Similarly,
2.5 bonus points were awarded for scores 2+ and 3+
if there was an accurate predication of IHC score and
PCMS deviated only 10% from the GT.
The weighted confidence was devised to measure
the credence of the predicted score by the submitted
algorithm. The criteria to measure the weighted con-
fidence wc were distinct for both truly and wrongly
classified cases. In cases where the predicted HER2
score pS matched with the GT with higher confidence
c, the weighted confidence amplified the confidence
value for true prediction, whereas wrong predictions
with high confidence were penalized accordingly, as
given in equation (1). This type of assessment is
important for the development of an interactive diag-
nostic module. The confidence value may indicate
those cases or regions where further examination by
the experts may be required before concluding the
final HER2 score.
wc ¼
2cc2
2 if ps ¼ GT
c2þ1
2 otherwise
(
ð1Þ
The third assessment criterion is a combination of
both agreement points and weighted confidence-based
evaluations. The combined points were calculated by
taking the product of two assessment criteria for each
case.
Results
C O N T E S T L E A D E R B O A R D S
Comprehensive results comprising all the submissions
for automated methods are shown in Table 3. The
teams in were ranked with respect to the combined
point-based assessment with bonus points. For the
off-site contest, the total possible points were 420 (28
cases with a maximum of 15 points each), whereas
for weighted confidence the maximum points were
28, 1 for each case. The top three-ranked teams with
respect to point based assessments were Team Indus,
MUCS-1 and MUCS-2, whereas according to weighted
confidence assessment the top-ranked teams were
VISILAB, FSUJena and MTB NLP. The combined
results rank the top three teams in the following
order: VISILAB, FSUJena and Huangch. The perfor-
mance of top-ranked teams including bonus points
and the trend for total points (without the bonus
points) can be seen in Figure 3. MUCS-1, MUCS-3,
CS_UCCGIP and MTB NLP achieved equal points, but
MUCS-1 secured more bonus points, as their PCMS
was more accurate compared to remaining counter-
parts. Similarly, Team VISILAB and Rumrocks
resulted in a tie where both teams attained equal
points, but the VISILAB method was more precise in
predicting PCMS. Comprehensive tables for all three
leaderboards are available for download from the con-
test website.
S U M M A R Y O F P R O P O S E D A U T O M A T E D M E T H O D S
Most of the automated methods (described in Data S2
and Figure S1) applied a supervised patch-based clas-
sification approach to solve this problem. The most
common pipeline was based on three main compo-
nents: (1) pre-processing including the methods to
identify the regions of interest for patch generation,
(2) classification based on handcrafted or neural net-
work learned features and (3) post-processing tech-
niques to aggregate the HER2 score at WSI level and
to estimate the PCMS. Deep learning, especially con-
volutional neural network (CNN)-based approaches,
dominated as eight of the top 10 methods were based
on CNN. The majority of the CNN architectures
[Team Indus, MUCS-(1–3), MTB NLP, VISILAB, Rum-
Rocks, FSUJena] were inspired from the state-of-the-
art deep neural networks.9,10
In pre-processing and patch extraction stage, most
of the teams followed the conventional thresholding
techniques with a combination of morphological
operators. These techniques are computationally less
expensive and generally work well, as background
regions lack any texture contents in contrast with
other tissue components. The MUCS-(1–3), MTB NLP,
VISILAB and FSUJena probe the regions of interest
manually through calibration or customized method-
ologies. These methods aimed to pick the best possible
regions for training their algorithm, generally with-
out affecting the testing phase. To segment tissue
regions, the RumRocks team implemented a deconvo-
lutional neural network (DCNN) and a two-dimen-
sional CNN for selection of patches based on their
texture. The Huangch team performed mean filtering
and stain normalization using the control tissue
© 2017 John Wiley & Sons Ltd, Histopathology, 72, 227–238.
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intensity values to calibrate the stain colour intensity
as a pre-processing step.
In the second step, most of the teams (specifically
the top 10) employed deep learning approaches,
whereas other teams such as CS_UCCGIP and
Huangch derived handcrafted characteristic curves
and employed standard machine learning approaches.
Team Indus used a combination of data-driven and
handcrafted features. They incorporated the average
control tissue intensity value along with learned
Table 3. A summary of results of all three assessment criteria for the automated human epidermal growth factor receptor
2 (HER2) scoring contest, ordered by the combined points criterion
Team Affiliation Points
Points +
bonus
Weighted
confidence Combined
VISILAB Universidad de Castilla-La Mancha 382.5 404.5 23.552 348.041
FSUJena Computer Vision Group, University of Jena 370 392 23 345
HUANGCH Bioinformatics Institute, Singapore 377.5 391.5 22.622 335.77
MTB NLP NLP Logix, LLC 390 405.5 22.937 335.737
VISILAB (density) Universidad de Castilla-La Mancha 377.5 391 21.878 322.067
Team Indus Indian Institute of Technology Guwahati 402.5 425 18.451 321.414
UC-CSSE-CGIP group University of Canterbury, New Zealand 390 395 21.07 316.05
MUCS-3 Computer Science, Maynooth University 390 411 20.434 300.813
HERcules University of Oxford 360 380 20.572 295.633
MUCS – 2 Computer Science, Maynooth University 385 413 19.51 290.171
Rumrocks Department of Statistics, University of Warwick 382.5 395 19.649 277.705
TissueGnostics TissueGnostics GmbH, Austria 365 366 17.78 266.41
Team Indus (Stainsep) Indian Institute of Technology Guwahati 332.5 345.5 18.451 250.715
MUCS – 1 Computer Science, Maynooth University 390 416 16.765 248.876
HersRockers Indian Institute of Technology Guwahati 320 330 17.318 223.007
VIP-UGR University of Granada 305 322.5 15.41 211.748
TartanSight Computational Biology, CMU 230 230 15.148 159.745
Cancer_Detector Indian Institute of Technology Kanpur 255 260 12.994 138.962
430
Leaderboard 1
420
410
400
390
380
370
360
350
340
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gch Figure 3. Combined results for
top-ranked teams with respect
to agreement and bonus
points. The trend shows the
significance of predicting
correctly the percentage of cell
membrane.
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features maps before passing them to the fully con-
nected layers. Some of the top-ranked teams deployed
variants of Alexnet9 and GoogLeNet10 for predicting
the HER2 score. The FSUJena team computed the
bilinear features after retrieving activations from con-
volutional layers of the AlexNet. The derived activa-
tions contain the learned feature maps representing a
d-dimensional w 9 h spatial grid. This approach
enables them to perform their analysis on top of the
learned features maps from CNN. In combination
with standard approaches for data regularization,
MTB NLP and RumRocks trained multiple models.
The final HER2 score and PCMS was estimated by
averaging over all the models. Additionally, a wide
range of data augmentation and regularization tech-
niques were employed to overcome the overfitting
issues. As in practice, the standard data augmenta-
tion techniques such as affine transformations (e.g.
rotation, flip, translation), random cropping, blurring
and elastic deformations were applied to train the
network. MUCS-2, MTB NLP and RumRocks broadly
used the data augmentation techniques to assist the
network to generalize well on unseen data.
In the final stage of pre-processing and predicting
the PCMS, most of the teams employed standard
image processing and machine learning approaches
on top of the results attained from the last step. A
Random Forest classifier was trained by MTB NLP to
produce the final class probabilities and to estimate
the PCMS. FSUJena simply used the mean tumour
cell percentage seen in the training set for a particu-
lar class as an estimate. Team Indus used both IHC-
and H&E-stained slides to estimate the PCMS by using
standard image processing approaches such as con-
tour detection, thresholding and morphological fea-
tures. All the remaining teams limited their analysis
to only IHC-stained images. All the submissions used
high-magnification images (910 or above), except
MUCS and Rumrocks, who used images from low res-
olution for selection of ROIs.
M A N V E R S U S M A C H I N E E V E N T
Organization
One way of evaluating the automated algorithms for
IHC (HER2) scoring is to perform comparative analy-
sis of the assessment of expert pathologists and auto-
mated methods for a handful of cases compared to
the scores for those cases as agreed by at least two
consultant breast pathologists (GT). On the day of the
contest workshop, we organized an event called Man
versus Machine. The main aim of this event was to
analyse the performance of automatic methods and
to explore the disagreements among conventional
and automatic methods. This type of analysis can
lead us to a more sophisticated protocol for automatic
HER2 scoring and to overcome the inter- and intra-
observer agreements that can be found in normal
practice.
The analysis between the expert’s agreement and
the evaluation of the automatic HER2 scoring method
was performed with a subset (15 cases) of the off-site
test data set. For this event, we set up an online web-
page for the pathologists. The webpage enabled the
experts to load and navigate (including pan and
zoom) through the WSI of those cases. Both IHC-
(HER2) and H&E-stained digital images were made
available to mimic the conventional scoring environ-
ment. On the contest day at Pathological Society
meeting 2016 we requested the expert pathologists to
score each case by providing the HER2 score, PCMS
and a confidence value.
Man versus machine results comparison
Table 4 summarizes the overall evaluation scores
achieved by each participant for this event. Each
table entry gives the cumulative score for all 15
cases, which indicates the overall performance. The
agreement-points-based assessment was used to eval-
uate the performance for this event. In total, we
received four responses from expert pathologists and,
as shown in Table 4 we ranked the top six submis-
sions, including the top three automated methods.
From submitted responses, three participant patholo-
gists reported themselves as ‘consultant pathologist’
and one as ‘trainee pathologist’, and all three marked
breast pathology as a subspeciality.
As can be seen in Table 4, one of the automated
methods slightly outperformed the top-performing
participant pathologist. These results point to the
potential significance of automated scoring methods
Table 4. Summary results for the Man versus Machine
event. The evaluation was carried out according to the
contest criteria as described in the Evaluation section
Rank Team name Score Bonus Score + bonus
1 Team Indus 220 12.5 232.5
2 Expert 2 210 20.5 230.5
3 VISILAB 212.5 15 227.5
4 MUCS-1 205 20.5 225.5
5 Expert 1 185 10 195
6 Expert 3 180 13 193
© 2017 John Wiley & Sons Ltd, Histopathology, 72, 227–238.
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and the recent advancements in digital pathology. It
is worth mentioning that automated HER2 scoring
algorithms submitted in this contest are not ready to
deploy in their current form, as they will require
extensive validation on a significantly large-scale data
set and also a great deal of input from experts to pre-
pare the GT on the larger data set.
Table 5 shows the pooled data for HER2 scoring
among the three top-ranked automated methods and
the scores from three participant pathologists and
comparison with the GT. Table 5 was determined
for the 15 cases selected from the off-site contest
data set. On the basis of HER2 scores, a 100%
agreement with the GT was observed for score 3+
among the participant pathologists and the auto-
mated methods. For the scores of 1+ and 2+, there
were disparities between the GT and the new scores.
In all cases except one, for both man and machine,
the error resulted from overcalling the score. Thus,
for score 1+, six of nine (67%) were overcalled as
2+ by humans while four of nine (44%) were over-
called by the machine algorithms. For the score of
2+, seven of 15 (46%) were overcalled as 3+ by
humans while machines overcalled one of 15 (6%)
as 3+ and one of 15 (6%) was undercalled as 1+.
Clinically, a score of 2+ is critical, as in routine
practice cases of score 2+ are recommended to
undergo FISH testing. It is equally important to
avoid predicting score 2+ as 1+ or 0 cases, as such
erroneous prediction will deny the further assess-
ment of HER2. As can be seen in Table 5, none of
the cases with score 2+ was misclassified by the par-
ticipant pathologists as either 1+ or 0, whereas for
one of the cases an automated method wrongly pre-
dicted a score of 2+ as 1+.
Most of the incorrect predictions by the participant
pathologists were found to be in cases where there
was considerable heterogeneity. Two such examples
are shown in Figure 4A–D. In tumour cells of HER2
score 2+, a pattern of weak to moderate complete
membrane staining is observed whereas for score 3+,
an intense (uniform) complete membrane staining is
observed. Estimating the complete membrane staining
is a difficult and highly subjective process, especially
for score 2+ and 3+, as it is extremely difficult to
detect subtle differences in the morphological appear-
ance for those cases.
Discussion
A major aim of organizing this contest was to provide
a platform for computer scientists and researchers to
contribute and to evaluate the performance of their
computer algorithms for automated IHC scoring of
HER2 in images from BCa tissue slides. Automated
scoring can overcome significantly the subjectivity
found, due to varying standards adopted by different
diagnostics laboratories. There is a current wealth of
literature11,12 using individual platforms (both freely
and commercially available) for digital analysis of
HER2 in BCa. This, however, was the first compar-
ison of platforms and algorithms, and provides a pilot
for independent comparison of computing algorithms
for HER2 assessment on a benchmark data set. The
contest highlights the wealth of potential carried by
artificial intelligence (AI) techniques for the assess-
ment of IHC slides.
The contest ‘training data set’ was selected deliber-
ately such that it contained a reasonable number of
cases from all HER2 scores, bearing in mind the need
for the training algorithms to learn features for each
score. For the test data set (both off- and on-site), the
GT was withheld at the time of image evaluation.
Results showed that the automated analysis per-
formed comparably to histopathologists. Many of the
algorithms achieved high accuracy – often close to
the maximum. Our main objective was to analyse the
performance of algorithms based on clinical rele-
vance, and hence the three particular evaluation cri-
teria described above were chosen. It may be possible
that other assessment criteria may influence the
ranking of comparative results.
The data from the Man versus Machine comparison
showed that, reassuringly, all participants (whether
human or computer) identified cases correctly with a
GT score of 3+. This means that no one in the cate-
gory would have been denied treatment. Similarly,
for the cases with a score of 0 or 1+, although there
was some overcalling, this never exceeded 2+ and
thus none would have received treatment without
further testing. The most problematic category was,
not unexpectedly, cases with a score of 2+ in both
human and machine evaluations. If overcalled as 3+,
the FISH negative subset would be overtreated. The
GT information for the FISH results were not released
to the participants, as the contest was aimed only at
comparing interpretation of HER2 IHC results. Hence,
most of the automated algorithms aimed at predicting
the equivocal cases as 2+. Table 5 incorporates the
FISH results for all the cases that were marked as 2+
in the test data GT (including the Man versus
Machine data set). From Man versus Machine cases
(15 in total), a score of 2+ (subsequently FISH nega-
tive) was overcalled by the machine as 3+ in only
one instance (VISILAB). In contrast, on three
© 2017 John Wiley & Sons Ltd, Histopathology, 72, 227–238.
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occasions (subsequently FISH-negative) the partici-
pant pathologists overcalled the score 2+ as 3+.
Moreover, for the remaining test data set (13 cases),
in three instances the score of 2+ (subsequently
FISH-positive) were predicted erroneously as either
1+ and 0 by the automated algorithms. Overall, the
Table 5. Combined matrix for agreement among the three experts and the top three automated methods based on agree-
ment points against the ground truth (GT) scores for 15 cases in the Man versus Machine event. Borderline case 7 was
deemed negative and cases 16 and19 were deemed positive for treatment decision (based on the human epidermal growth
factor receptor 2:chromosome 17 centromere (HER2:CEP17) amplification ratio for HER2 over-expression: 1.96, 2.1 and
2.07, respectively
Case Ground truth FISH results Expert 1 Expert 2 Expert 3 Team Indus Visilab MUCS-1
1 2+ Negative 3+ 2+ 2+ 2+ 2+ 2+
2 0 – 0 1+ 1+ 1+ 1+ 0
3 3+ – 3+ 3+ 3+ 3+ 3+ 3+
4 0 – 1+ 1+ 1+ 0 1+ 1+
5 1+ – 2+ 1+ 2+ 1+ 2+ 1+
6 3+ – 3+ 3+ 3+ 3+ 3+ 3+
7 2+ Borderline amplified 3+ 3+ 3+ 2+ 2+ 2+
8 2+ Negative 3+ 2+ 3+ 2+ 3+ 2+
9 3+ – 3+ 3+ 3+ 3+ 3+ 3+
10 3+ – 3+ 3+ 3+ 3+ 3+ 3+
11 1+ – 1+ 1+ 2+ 0 1+ 1+
12 2+ Positive 2+ 2+ 3+ 2+ 2+ 2+
13 1+ – 2+ 2+ 2+ 2+ 2+ 1+
14 2+ Negative 2+ 2+ 2+ 2+ 2+ 1+
15 0 – 0 1+ 0 0 1+ 0
16 2+ Borderline amplified – – – 0 1+ 2+
17 2+ Negative – – – 2+ 2+ 2+
18 2+ Positive – – – 2+ 1+ 2+
19 2+ Borderline amplified – – – 2+ 2+ 2+
20 1+ – – – – 1+ 1+ 1+
21 1+ – – – – 1+ 1+ 2+
22 0 – – – – 1+ 0 1+
23 1+ – – – – 0 1+ 1+
24 1+ – – – – 0 1+ 2+
25 3+ – – – – 3+ 3+ 3+
26 0 – – – – 1+ 0 1+
27 0 – – – – 0 0 1+
28 0 – – – – 0 0 0
FISH, Fluorescence in-situ hybridization.
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results indicate that further fine-tuning will be
required for 2+ cases with AI. While it is encouraging
that automated HER2 scoring algorithms may have
sufficient potential as a direct comparison to human
diagnosis, it is probably worthwhile to reflect that the
number of pathologists actually joining the contest
was small (only four) and it would have been better
to compare the pathologist’s assessment of the slides
on a reporting microscope rather than a computer for
a fairer comparison to real-life practice.
Conventionally, expert pathologists often switch
back and forth between the IHC and H&E slides to
map the invasive tumour regions for estimating the
percentage of complete membrane staining. With the
exception of one of the participants (Team Indus),
most of the algorithms reported in this paper have
avoided the use of H&E slides, although the use of
H&E slide for the automatic detection of ductal carci-
noma in situ (DCIS) regions cannot be ruled out. In
addition, the task of predicting the PCMS is extremely
subjective, as the expert has to make an estimation
on the basis of the physical appearance of the stained
invasive tumour region. The semi-automated methods
could provide a comprehensive quantitative analysis
on the selected region of interest to assist the experts
in estimating the PCMS and HER2 score, especially in
borderline cases. As HER2 immunoscoring relies not
only on intensity but the completeness of membrane
(A)
(B)
(C)
GT
2
Expert 1
3
Expert 2
2
Expert 3
3
Team Indus
2
MUCS 1
3
VISILAB
2
GT
2
Expert 1
2
Expert 2
2
Expert 3
3
Indus
2
MUCS 1
2
VISILAB
2
(D)
Figure 4. Examples showing
immunohistochemistry (IHC)-
stained whole slide images
(WSIs) (A,C) and zoomed-in
cross-sectional area (B,D) with
corresponding human
epidermal growth factor
receptor 2 (HER2) ground
truth (GT) scores marked by
expert pathologists and
predictions from the top
automated methods.
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positivity, automated scoring may be helpful as
demonstrated by Br€ugmann et al.,13 who proposed
scoring of HER2 based on an algorithm evaluating
the cell membrane connectivity.
This study shows that automated IHC scoring algo-
rithms can provide a quantitative assessment of mor-
phological features that can assist in objective
computer-assisted diagnosis and predictive modelling
of the outcome and survival.14 We have demon-
strated the potential significance of digital imaging
and automated tools in histopathology. In the context
of breast histopathology, whereby almost all the inva-
sive tumour cases are considered for HER2 testing,
an automated or semi-automated scoring method has
potential for deployment in routine practice. Despite
all these advances, several challenges remain for the
AI algorithms to be optimized and become part of
routine diagnosis. It is worth noting that serious opti-
mization will be needed for automated methods while
processing a whole-slide image. Some methods
required more than 3 h per case which, in the ‘real
world’ of diagnostic service delivery, is not feasible.
Another limitation of this contest was that the image
data were collected from a single site using a single
scanner. A potential extension would be to collect
data from multiple pathology laboratories with HER2
scores marked by different experts and images
scanned using a variety of different machines. This
would also test the differences inherent in staining
quality that may affect such procedures. Such
enhancements could overcome significantly the over-
fitting to one particular data set that may occur in
the automated scoring methods. In moving across
systems other laboratories, for example, have
acknowledged the challenges in reaching the opti-
mum Aperio algorithm parameters to provide results
that were equivalent to those of the ‘automated cellu-
lar imaging system’ (ACIS) or ‘cell analysis system’
(CAS 200) quantitation systems,15 which are fully
automated environments for detecting cells based on
intensity characteristics and handcrafted features
found in IHC-stained images. Therefore, there is a
need to learn throughout comparative systems, for
which the current study provided a valid starting-
point. Also, the study highlights the need for dialogue
between histopathologists and informaticians to
understand the correct identification of tissue com-
partments relevant for assessment, correct morphol-
ogy (normal versus in-situ versus invasive) and
stromal versus tumour stain. Algorithms will also
need to be trained to the natural acceptable variation
in staining hues and intensities (intra- and interlabo-
ratories) to work effectively during routine practice.
All cases with score 2+ are recommended routinely
for further FISH testing to validate HER2 overexpres-
sion at the gene level. It would be an added advan-
tage if the automated methods could be trained with
FISH GT to predict the final outcome, and the poten-
tial for automated algorithms in calling the actual
final HER2 status with reproducible accuracy could
be demonstrated. For this, a larger series with 2+
cases alone with FISH data would need to be tested.
Indeed, there have been other promising studies that
indicate that automated image analysis for HER2
instead of manual assessment may reduce the need
for supplementary FISH testing by up to 68%.16 In a
diagnostic setting, this would reduce costs and turn-
around time significantly. During the last decade, IHC
staining has become ubiquitous in pathology labora-
tories globally and the role of IHC evaluation in a
high-throughput setting becomes key for IHC-based
companion diagnostics. Other possible extensions of
digital pathology could be to automate the overex-
pression of the programmed death 1 (PD-1) receptor
and its ligand (PD-L1) to evaluate anaplastic lym-
phoma kinase (ALK) protein and proto-oncogene tyr-
osine-protein kinase ROS1 in lung cancers.17 The AI-
based algorithms would be more effective if IHC stain-
ing and scoring methods were treated as a composite
assay.18,19 The varying staining protocols and scoring
parameters may restrain the effectiveness of AI-based
automated scoring algorithms, including the HER2
scoring, but with sufficiently variable data from differ-
ent centres AI algorithms could be trained to over-
come that problem.
This contest provides a baseline for computer
science and computational pathology researchers for
automated/semi-automated scoring and computer-
assisted diagnosis (CAD) tools to assist the patholo-
gists in daily routine analysis. The contest is now
over but the registration and the web-portal will
remain open for future participants to make novel
contributions to automated HER2 scoring.
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Data S1. Contest format.
Table S1. The ground truth score for 52 cases from
the training dataset with percentage of cells with
complete membrane staining. The boderline case 63
was deemed negative and the amplification ratio for
Her2 over-expression was 1.92.
Data S2. Description of automated methods.
Figure S1. Characteristics curves and the corre-
sponding Her2 score. The x-axis denotes range of the
saturation value whereas y-axis denotes the calcu-
lated percentage from saturation limits. The predicted
Her2 scores are also shown for each curve.
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